Cancer News and Research

Latest Cancer News and Research

Third-quarter fiscal 2009 results announced by MDS

MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today reported financial results for the three-month period ended July 31, 2009. MDS reported total revenue of $199 million, a net loss of $62 million and a loss per share of $0.51 for the third quarter of 2009, compared with $252 million in total revenue, a net loss of $10 million and a loss per share of $0.08 for the same period last year.

10 Sep 2009

Phase Forward's Empirica Suite to be showcased at the 3rd annual conference

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will participate in the 3rd annual World Drug Safety Congress Europe, to be held September 15-18 at the Bloomsbury Hotel in London, U.K.

10 Sep 2009

Cord Blood America to complete its new Las Vegas laboratory on schedule

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, said today that it is on schedule to complete the construction of its new Las Vegas laboratory by the first week of October.

10 Sep 2009

EPO issues grant for a patent in Kreutzer-Limmer III patent series

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.

10 Sep 2009

QIAGEN's new QIAsafe DNA blood products launched

Biomatrica, Inc. and QIAGEN announce the launch of QIAGEN's new QIAsafe DNA Blood Products, the first dry blood storage available on a matrix based on Biomatrica's innovative SampleMatrix(R) technology.

From QIAGEN Manchester Limited 10 Sep 2009

Applications for the Pancreatic Cancer Action Network and AACR 2010 Research Grants Program invited

The Pancreatic Cancer Action Network, in partnership with the American Association for Cancer Research (AACR), is now accepting applications for the 2010 Research Grants Program. This year's grants program will be administered through the AACR's rigorous peer-review system to ensure the highest quality science is supported. The grant terms will begin on July 1, 2010.

10 Sep 2009

Cancer Research UK launches a new Cancer Centre at Cardiff

Cardiff today (Thursday) joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

10 Sep 2009

Complete Genomics sequences and delivers 14 human genomes

Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009.

10 Sep 2009

SRA to provide scientific peer review services to Cancer Prevention and Research Institute of Texas

SRA International, Inc. (NYSE: SRX), a leading provider of technology and strategic consulting services and solutions to government organizations and commercial clients, today announced it has won a contract from the Cancer Prevention and Research Institute of Texas (CPRIT) to provide scientific peer review services. The contract is worth $16.2 million over five years, if all options are exercised. Work on the contract began July 1, 2009.

10 Sep 2009

Business operations to be hit in the event of H1N1 outbreak

In a national survey of businesses that looks at their preparations for a possible widespread H1N1 outbreak, Harvard School of Public Health (HSPH) researchers found that only one-third believe they could sustain their business without severe operational problems if half their workforce were absent for two weeks due to H1N1 (also known as "swine flu").

10 Sep 2009

Lack of awareness in aged men reagarding prostate cancer treatment options

Prostate cancer remains one of the most commonly diagnosed cancers in the United States. In fact, one in six men will develop prostate cancer. It is also the second-leading cause of cancer death in the United States. But a recent survey suggests that many men at risk for the cancer still aren't aware of all available treatment options.

10 Sep 2009

Nanobio hybrids for brain cancer therapy

In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. The study is scheduled for the Sept. 9 issue of ACS' Nano Letters, a monthly journal.

10 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

New type of stem cell in the prostate may be a source for prostate cancer, say researchers

A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study by researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.

10 Sep 2009

New Influenza A/H1N1 detection kit launched

QIAGEN, today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance of the swine flu pandemic. QIAGEN’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes “swine flu”, as well as of all other known Influenza A and B virus strains.

10 Sep 2009

Vespa USA supports breast cancer awareness programs

The next time you see a distinctively pink Vespa zooming by, it might just be one of the Vespa LX 50 scooters that over a dozen non-profit agencies devoted to battling breast cancer are adding to their autumn Breast Cancer Awareness initiatives.

10 Sep 2009

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Lead exposure may result in cardiovascular mortality

Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.

10 Sep 2009

Oral and throat cancers linked to human papilloma virus

Infection by the human papilloma virus (HPV), the most common sexually transmitted disease, has been linked to more than one third of all oral and throat cancers according to Dr. Solomon Hamburg, president of the prestigious Tower Cancer Research Foundation.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009